These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. BRAF and NRAS mutations in spitzoid melanocytic lesions. Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476 [TBL] [Abstract][Full Text] [Related]
27. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. McClenahan P; Lin LL; Tan JM; Flewell-Smith R; Schaider H; Jagirdar K; Atkinson V; Lambie D; Prow TW; Sturm RA; Soyer HP JAMA Dermatol; 2014 Oct; 150(10):1079-82. PubMed ID: 24695877 [TBL] [Abstract][Full Text] [Related]
28. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Takata M; Murata H; Saida T Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535 [TBL] [Abstract][Full Text] [Related]
29. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi. Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123 [TBL] [Abstract][Full Text] [Related]
30. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627 [TBL] [Abstract][Full Text] [Related]
31. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447 [TBL] [Abstract][Full Text] [Related]
32. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Uribe P; Wistuba II; González S Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284 [TBL] [Abstract][Full Text] [Related]
33. Mutations of the BRAF gene in benign and malignant melanocytic lesions. Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620 [TBL] [Abstract][Full Text] [Related]
34. BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter? Saroufim M; Novy M; Taraif S; Habib RH; Loya A; Rauscher B; Kriegshäuser G; Oberkanins C; Khalifeh I J Eur Acad Dermatol Venereol; 2014 May; 28(5):615-25. PubMed ID: 23906414 [TBL] [Abstract][Full Text] [Related]
37. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Lee JH; Choi JW; Kim YS Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657 [TBL] [Abstract][Full Text] [Related]
38. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711 [TBL] [Abstract][Full Text] [Related]
39. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765 [TBL] [Abstract][Full Text] [Related]
40. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. Yeh I; von Deimling A; Bastian BC J Natl Cancer Inst; 2013 Jun; 105(12):917-9. PubMed ID: 23690527 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]